Clinical Values of Serum Platelet-Activating Factor in Hypertensive Disorders Complicating Pregnancy

Overview

Journal Kidney Blood Press Res

Publisher Karger

Date 2025 Jan 8

PMID 39778544

Authors

Shasha Liu

Qianyu Lan

Weiling Li

Jiefang Zhang

Liman Fu

Yanlei Xu

Yuan Li

Affiliations

Soon will be listed here.

Abstract

Introduction: Serum platelet-activating factor (PAF) was proven to be associated with gestational hypertension. However, the predictive value of serum PAF at early pregnancy for the occurrence and outcomes of hypertensive disorders complicating pregnancy (HDCP) remained unclear.

Methods: The demographic and clinical characteristics of patients were compared among the different subgroups. The serum PAF level was determined using an enzyme-linked immunosorbent assay. The predictive value of serum PAF for the occurrence and outcomes of HDCP was evaluated using receiver operating characteristic curve analysis. The correlation of serum PAF with blood pressure was assessed using Spearman analysis.

Results: Both systolic blood pressure and diastolic blood pressure were significantly higher in HDCP patients, as well as the serum levels of TNF-α and IL-1β at diagnosis/enrollment, while serum levels of IL-10 showed the opposite trend. Serum PAF levels were significantly higher in patients with HDCP compared to normal pregnant women. Furthermore, serum PAF levels were higher in HDCP patients with mild preeclampsia compared to those with gestational hypertension and even more elevated in HDCP patients with severe preeclampsia at the early pregnancy stage and at diagnosis. In HDCP patients, increased serum PAF levels at early pregnancy and at diagnosis were associated with poor outcomes. Additionally, serum PAF levels could predict the occurrence of HDCP and poor outcomes.

Conclusion: Serum PAF from HDCP patients at both the early pregnancy and diagnosis stages could effectively predict the occurrence and outcome of HDCP.

References

Folk D . Hypertensive Disorders of Pregnancy: Overview and Current Recommendations. J Midwifery Womens Health. 2018; 63(3):289-300. DOI: 10.1111/jmwh.12725. View

Snyder F . Platelet-activating factor and its analogs: metabolic pathways and related intracellular processes. Biochim Biophys Acta. 1995; 1254(3):231-49. DOI: 10.1016/0005-2760(94)00192-2. View

Ji W, Chen J, Mi Y, Wang G, Xu X, Wang W . Platelet-activating factor receptor activation promotes prostate cancer cell growth, invasion and metastasis via ERK1/2 pathway. Int J Oncol. 2016; 49(1):181-8. DOI: 10.3892/ijo.2016.3519. View

Rowland B, Vermillion S, Roudebush W . Elevated circulating concentrations of platelet activating factor in preeclampsia. Am J Obstet Gynecol. 2000; 183(4):930-2. DOI: 10.1067/mob.2000.108894. View

Howarth S, Marshall L, Barr A, Evans S, Pontre M, Ryan N . Platelet indices during normal pregnancy and pre-eclampsia. Br J Biomed Sci. 1999; 56(1):20-2. View

Kasperska-Zajac A, Brzoza Z, Rogala B . Platelet-activating factor (PAF): a review of its role in asthma and clinical efficacy of PAF antagonists in the disease therapy. Recent Pat Inflamm Allergy Drug Discov. 2008; 2(1):72-6. DOI: 10.2174/187221308783399306. View

Benedetto C, Massobrio M, Bertini E, Abbondanza M, Enrieu N, Tetta C . Reduced serum inhibition of platelet-activating factor activity in preeclampsia. Am J Obstet Gynecol. 1989; 160(1):100-4. DOI: 10.1016/0002-9378(89)90097-5. View

Lindsberg P, Hallenbeck J, Feuerstein G . Platelet-activating factor in stroke and brain injury. Ann Neurol. 1991; 30(2):117-29. DOI: 10.1002/ana.410300202. View

Bernstein P, Martin Jr J, Barton J, Shields L, Druzin M, Scavone B . National Partnership for Maternal Safety: Consensus Bundle on Severe Hypertension During Pregnancy and the Postpartum Period. Obstet Gynecol. 2017; 130(2):347-357. DOI: 10.1097/AOG.0000000000002115. View

10.

Mullers S, Burke N, Flood K, Cowman J, OConnor H, Cotter B . Altered Platelet Function in Intrauterine Growth Restriction: A Cause or a Consequence of Uteroplacental Disease?. Am J Perinatol. 2016; 33(8):791-9. DOI: 10.1055/s-0036-1572428. View

11.

Bernstein P, Martin Jr J, Barton J, Shields L, Druzin M, Scavone B . Consensus Bundle on Severe Hypertension During Pregnancy and the Postpartum Period. J Obstet Gynecol Neonatal Nurs. 2017; 46(5):776-787. DOI: 10.1016/j.jogn.2017.05.003. View

12.

Xu B, Gao L, Wang L, Tang G, He M, Yu Y . Effects of platelet-activating factor and its differential regulation by androgens and steroid hormones in prostate cancers. Br J Cancer. 2013; 109(5):1279-86. PMC: 3778313. DOI: 10.1038/bjc.2013.480. View

13.

Maayeh M, Costantine M . Prevention of preeclampsia. Semin Fetal Neonatal Med. 2020; 25(5):101123. PMC: 8236336. DOI: 10.1016/j.siny.2020.101123. View

14.

Montrucchio G, Alloatti G, Camussi G . Role of platelet-activating factor in cardiovascular pathophysiology. Physiol Rev. 2000; 80(4):1669-99. DOI: 10.1152/physrev.2000.80.4.1669. View

15.

Antza C, Cifkova R, Kotsis V . Hypertensive complications of pregnancy: A clinical overview. Metabolism. 2017; 86:102-111. DOI: 10.1016/j.metabol.2017.11.011. View

16.

Wang R, Liu J, Qiao Y, Wang X, Chen J, Ma Y . Efficacy of atosiban combined with ritodrine on spontaneous threatened preterm birth and its effect on PAF and fFN levels. Am J Transl Res. 2022; 14(11):7942-7950. PMC: 9730057. View

17.

Young B, Levine R, Karumanchi S . Pathogenesis of preeclampsia. Annu Rev Pathol. 2010; 5:173-92. DOI: 10.1146/annurev-pathol-121808-102149. View

18.

Montrucchio G, Alloatti G, Tetta C, Roffinello C, Emanuelli G, Camussi G . In vitro contractile effect of platelet-activating factor on guinea-pig myometrium. Prostaglandins. 1986; 32(4):539-54. DOI: 10.1016/0090-6980(86)90036-5. View

19.

TePoel M, Saftlas A, Wallis A . Association of seasonality with hypertension in pregnancy: a systematic review. J Reprod Immunol. 2011; 89(2):140-52. DOI: 10.1016/j.jri.2011.01.020. View

20.

Nadar S, Lip G . Platelet activation in the hypertensive disorders of pregnancy. Expert Opin Investig Drugs. 2004; 13(5):523-9. DOI: 10.1517/13543784.13.5.523. View